Alluvi, previously BI 4744, represents a promising advance in weight control therapy. This dual activator targeting both GLP-1 and GIP receptors demonstrates impressive effectiveness in patient studies, possibly https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/